Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
7 hedge funds and large institutions have $132K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
8% more capital invested
Capital invested by funds: $122K → $132K (+$10K)
0% more funds holding
Funds holding: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.43K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $50K | – | – | – |
|
|
PA
2
Perceptive Advisors
New York
| $48K | – | – | – |
|
|
MWNA
3
Marshall Wace North America
New York
| $15K | – | – | – |
|
|
PC
4
PointState Capital
New York
| $12K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4K | +$2.43K | +16,637 | +84% |
|
|
MIM
6
Monashee Investment Management
Boston,
Massachusetts
| $3K | – | – | – |
|
OTLKW Hedge Fund Activity: Q3 2019 in Review
7 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q3 2019, worth a combined $132K — up 8.2% from $122K a quarter earlier.
Fund positioning in OTLKW was balanced in Q3 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.43K.
- 7 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $132K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q3 2019, up 8.2% quarter-over-quarter.
- 0 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q3 2019 and 0 closed out.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q3 2019 was Susquehanna International Group, an estimated $2.43K added.
Based on aggregated 13F filings for Q3 2019.